10 Sanofi business development leaders
A biotech out-licensing an asset to Sanofi, or negotiating a research collaboration, would find business development counterparts here: the Global Head of Business Development and Licensing, the Head R&D Transactions and leads for immunology and inflammation, DCV, MS neurology and rare diseases, vaccines and technology platforms. Nine hold current Sanofi roles, and Donna Martin was Global Head Business Development & Licensing Vaccines until 2023.
Professionals to explore
Bernd Rosenstock
LinkedInExperience: Director, DCV Business Development & Licensing · Sanofi
$539 per 30-minute call
Bernd Rosenstock is Director, DCV Business Development & Licensing at Sanofi in Frankfurt (since 2017), following Director, R&D Transactions (2005–2017). Earlier roles were Director, Corporate Development at Aventis Pharma AG (1999–2004) and Alliance Manager at Hoechst AG (1998–1999), so R&D transaction structuring and alliance management questions fit Bernd.
Is this you? Claim your profile and get paid for calls.
Beth Mathiesen
LinkedInExperience: Head, Sanofi Pasteur BD and Licensing · Sanofi
$1,010 per 30-minute call
Beth Mathiesen came to vaccines deal-making from patent work at Sanofi: Director--Sanofi Pasteur Intellectual Property (2012–2015), Senior Director--Sanofi Pasteur Intellectual Property (2015–2016), Global Head of Vaccines Patents (2017–2019) and Principal Counsel, Strategy, BD and M&A - Patents (2019–2021). Since 2021 Beth has been Head, Sanofi Pasteur BD and Licensing in Cambridge, Massachusetts, a fit for questions where vaccine licensing and IP meet.
Is this you? Claim your profile and get paid for calls.
Brian S. Bronk
LinkedInExperience: Head of Business Development, MS Neurology, Rare & Rare Blood & Innovative Technologies · Sanofi
$943 per 30-minute call
Rare diseases run through Brian S. Bronk's Sanofi roles: Head of External Innovation, Rare Diseases (2017–2018), Head Of Business Development, Rare Diseases and Rare Blood Disorders (2019) and Head of Business Development, MS Neurology, Rare & Rare Blood & Innovative Technologies since 2019. Brian was also Principal, Sunrise, Sanofi Global R&D (2014–2016) and Co-Founder and CSO of Armada (2013–2014), which suits start-up biotechs seeking a partner in neurology or rare disease.
Is this you? Claim your profile and get paid for calls.
Donna Martin
LinkedInExperience: Former Global Head Business Development & Licensing Vaccines · Sanofi
$1,683 per 30-minute call
Donna Martin was Global Head Business Development & Licensing Vaccines at Sanofi, based in Swiftwater, Pennsylvania, from 2019 to 2023. As a former head of vaccines business development and licensing, Donna suits questions on vaccines licensing deals at a large pharma company.
Is this you? Claim your profile and get paid for calls.
Fabio Hoyos
LinkedInExperience: Senior Director, Business Development · Sanofi
$471 per 30-minute call
Fabio Hoyos describes helping lead M&A, in-licensing, out-licensing, equity investments and commercial and clinical partnerships, and has been Senior Director, Business Development at Sanofi since 2024. At Pfizer, Fabio was Manager, Corporate Development (2019–2021), Senior Manager, Corporate Development (2021–2023) and Director, Transactions and Valuations (2023–2024), after Private Equity Investment Professional at Palladium Equity Partners, LLC (2016–2019). Deal valuation questions fit Fabio.
Is this you? Claim your profile and get paid for calls.
Gosia Ciesiolka
LinkedInExperience: Senior Director Business Development R&D Transactions · Sanofi
$471 per 30-minute call
With 21 years in business development, Gosia Ciesiolka describes evaluating, structuring and executing transactions across therapeutic areas and technology and platform deals, including in- and out-licensing and research collaborations. Gosia has been Senior Director Business Development R&D Transactions at Sanofi since 2025, after Senior Director Business Development Immunology & Inflammation (2020–2025) and Senior Director Business Development Diabetes & Primary Care (2018–2019).
Is this you? Claim your profile and get paid for calls.
Hubert Haag
LinkedInExperience: Director Technology Platforms - Global Business Development & Licensing · Sanofi
$471 per 30-minute call
Hubert Haag has been Director Technology Platforms - Global Business Development & Licensing at Sanofi since 2017 and held Director, Global Sourcing & External Opportunities Lead Identification (2009–2017). Earlier Sanofi roles were Global Management Lead Discovery Technologies (2004–2008) and Head Natural Products Screening (2000–2003), after Head Natural Products & Pharmacokinetics at Boehringer Ingelheim (1998–2000). Platform technology deals are Hubert's area.
Is this you? Claim your profile and get paid for calls.
Michael Palladinetti
LinkedInExperience: Global Head of Business Development and Licensing · Sanofi
$2,019 per 30-minute call
Michael Palladinetti has been Global Head of Business Development and Licensing at Sanofi in Cambridge, Massachusetts since 2022, after Global Head of Oncology and Immunology Business Development & Licensing (2018–2022) and Head of Oncology Business Development & Licensing (2017–2018). Before Sanofi, Michael was Director, Business Development at Bristol Myers Squibb (2013–2017) and Takeda Oncology (2012–2013), a record that fits oncology and company-wide licensing questions.
Is this you? Claim your profile and get paid for calls.
Murielle Gitton
LinkedInExperience: Head R&D Transactions · Sanofi
$875 per 30-minute call
Murielle Gitton's roles are all at Sanofi: Postdoctoral Fellow (2005–2007), Research Contract Manager (2007–2010), Director, Sanofi Genzyme Transactions, Gobal Business Development & Licensing (2010–2022) and Head R&D Transactions since 2022. That path from research contracts to transactions makes Murielle a fit for questions on contract terms in R&D collaborations.
Is this you? Claim your profile and get paid for calls.
Rachael Felberbaum
LinkedInExperience: Senior Director of Business Development, Immunology and Inflammation · Sanofi
$471 per 30-minute call
Rachael Felberbaum has covered several Sanofi deal areas: Director Business Development and Licensing, Vaccines (2018–2021), Senior Director, Global Transactions (2021–2022), Senior Director of Business Development, Oncology (2022–2023) and Senior Director of Business Development, Immunology and Inflammation since 2023. Rachael was also Senior Director, Business Development at Protein Sciences Corporation (2015–2017), so questions on business development across therapeutic areas fit.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
Michael Palladinetti is the pick for how the whole business development and licensing function sets priorities. For structuring questions, go to the R&D transactions leads Murielle Gitton and Gosia Ciesiolka, or Fabio Hoyos on valuation; for a specific asset, match the area: Rachael Felberbaum (immunology and inflammation), Bernd Rosenstock (DCV), Brian S. Bronk (neurology and rare diseases), Beth Mathiesen or former head Donna Martin (vaccines) and Hubert Haag (technology platforms).
Questions to take into the conversation
- 01What does a large pharma business development team need to see in an early data package before opening licensing talks?
- 02How are R&D collaborations structured differently from straight in-licensing deals?
- 03How do vaccine licensing deals differ from therapeutic deals in terms and diligence?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.